Synapse - Howard Scher

Results (1133)

Evaluation of the patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) with abiraterone acetate plus prednisone (AAP), degarelix (D), or the combination in men with biochemically recurrent prostate cancer (BCRPC)

Meeting Abstract

Autio, K. A.; Antonarakis, E. S.; Baser, R.; Stein, M. N.; Shevrin, D. H.; Vaishampayan, U. N.; Mayer, T. M.; Morris, M. J.; Slovin, S. F.; Heath, E. I.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TRITON2

Meeting Abstract

Abida, W.; Bryce, A. H.; Vogelzang, N. J.; Amato, R. J.; Percent, I. J.; Shapiro, J. D.; McDermott, R. S.; Hussain, A.; Patnaik, A.; Petrylak, D. P.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Metacure: Multi-arm multimodality therapy for very high risk localized and low volume metastatic prostatic adenocarcinoma

Meeting Abstract

Teo, M. Y.; Taplin, M. E.; Eastham, J. A.; Benoliel, H.; Kibel, A. S.; McBride, S. M.; Nguyen, P. L.; Gopalan, A.; Lis, R.; Scher, H. I.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD

Meeting Abstract

Smith, M. R.; Sandhu, S. K.; Kelly, W. K.; Scher, H. I.; Efstathiou, E.; Lara, P.; Yu, E. Y.; George, D. J.; Chi, K. N.; Summa, J.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Morphology-predicted, large-scale transition (LST) number in circulating tumor cells (CTC) as a biomarker of chromosomal instability (CIN) to assess early resistance to standard of care (SOC) drugs in mCRPC

Meeting Abstract

Scher, H. I.; Schonhoft, J.; Hullings, M.; Carbone, E.; Barnett, E.; Sutton, R.; Jendrisak, A.; Landers, M. A.; Wang, Y.; Dittamore, R.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Assessment of circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer

Meeting Abstract

Scher, H. I.; McCormack, R. T.; Molina, A.; Smith, M. R.; Dreicer, R.; Saad, F.; De Wit, R.; Fizazi, K.; Aftab, D. T.; Limon, A.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Clinicopathologic and genomic characterization of parenchymal brain metastases (BM) in prostate cancer (PCa)

Meeting Abstract

Mota, J. M. S. C.; Teo, M. Y.; Knezevic, A.; Bambury, R. M.; Hatzoglou, V.; Autio, K. A.; Abida, W.; Gopalan, A.; Fine, S.; Danila, D. C.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Tumor testing in men with prostate cancer to predict for germline DNA-damage repair mutations

Meeting Abstract

Carlo, M. I.; Kemel, Y.; Breen, K.; Cadoo, K. A.; Walsh, M. F.; Abida, W.; Autio, K. A.; Danila, D. C.; Kampel, L. J.; Morris, M. J.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

The clinical impact of bone scan (BS) flare with enzalutamide (ENZA) in men with metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Armstrong, A. J.; Al-Adhami, M.; Lin, P.; Parli, T.; Sugg, J.; Steinberg, J. L.; Tombal, B. F.; Sternberg, C. N.; De Bono, J. S.; Scher, H. I.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

The Polycomb repressor complex 1 promotes recruitment of myeloid-derived suppressor cells and immune evasion during bone colonization in castration-resistant prostate cancer

Meeting Abstract

Su, W.; Zhang, B.; Han, H.; Chakraborty, G.; Zhou, B.; Su, J.; Yang, G.; Ouerfelli, O.; Rosen, N.; Scher, H. I.; more...
Cancer Research (2019)

Fulltext@MSK | Save